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Summary The influence of smoking on lamotrigine (LTG) serum levels in 44 patients
with epilepsy treated with LTG in monotherapy was examined. Fifteen patients were
smokers (range: three cigarettes per month — three packages per day) and 29 were
non-smokers. Analyzing 204 samples, smokers had a significantly lower serum level-
to-dose ratio than non-smokers (0.0657 mmol mg/l (smokers) vs. 0.0785 mmol mg/
(non-smokers)) ( p = 0.0014). Analyzing onlymale patients, the same relationship with
an almost equally high level of significance could be demonstrated ( p = 0.008). Our
data indicate that the demonstrated effect of smoking on LTG metabolism is likely to
be mediated via UDPGT2B7, as LTG is not a substrate of cytochrome P450 isoenzymes
and UDPGT1A4 activity may not be affected by nicotine, but the exact mechanism
underlying the demonstrated effect remains uncertain. These findings are likely to be
independent from hormonal changes, as they could also be reproduced in the group of
male patients. Therefore, the effect of smoking on blood levels of LTG has to be taken
into account in the evaluation of treatment with this drug.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Lamotrigine (LTG) is widely used for the treatment
of epilepsies with simple- and complex-partial as
well as generalized seizures.1 Many pharmacoki-
netic effects of other anticonvulsive drugs or other
agents (e.g. hormones) on serum levels of LTG have
been described.2—4 As influences of smoking on* Corresponding author at: Department of Neurology, Julius-
Maximilians-University Wu¨rzburg, Josef-Schneider-Str. 11, 97080
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doi:10.1016/j.seizure.2008.05.009drugs metabolized by glucuronidation such as lor-
azepam and oxazepam have been reported and LTG
is also substrate for glucuronidation,5 an effect on
LTG appears to be possible. Furthermore, nicotine is
known to decrease the anticonvulsive effect of LTG
in a mice model.6Methods
LTG serum levels of 44 Caucasian patients with
epilepsy treated with LTG in monotherapy were
retrospectively examined. Except a possible intake
of oral contraceptive pills in female patients, no
other medication that could influence LTG serum. Published by Elsevier Ltd. All rights reserved.
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Table 1 Characteristics of patients as described in the text
Smokers Non-smokers
Number of patients 15, 10 female and 5 male 29, 15 female and 14 male
Number of measurements 61 143
Age (mean  S.D.) 33 (10.25) 34 (14.23)
Cigarettes/month (mean  S.D.) 357 (530) 0 (0)
LTG-dose (mg) (mean  S.D.) 423 (217) 437 (199)
LTG serum level (mmol/l) (mean  S.D.) 27.71 (15.56) 32.95 (15.89)
LTG serum level-to-dose ratio
(mmol mg/l) (mean  S.D.)
0.0657 (0.027) 0.0785 (0.029)
Note the difference in sex ratio between smokers and non-smokers (LTG: lamotrigine, S.D.: standard deviation).levels were taken. Fifteen of the patients (10
females and five males) were smokers (three cigar-
ettes/month — three packages/day, five patients
smoked less than 10 cigarettes/day) and 29 (15
females, 14 males) non-smokers. Allowing repeated
measurements in single patients, 204 samples were
collected on various daytimes and analyzed. Blood
samples were taken with sufficient time to the last
alteration in the dose of LTG, to assume a steady
state. All patients were recruited as in- or outpa-
tients in our epilepsy center. LTG serum levels were
determined using reverse phase high performance
liquid chromatography (HPLC) utilizing acetonni-
trile—phosphate buffer. The statistical comparison
between LTG serum levels was performed by SPSS
14.0 Software using K&S-Test, correlation by Pear-
son and one-factor ANOVA.Results
Characteristics of the study population are given in
Table 1.
All data showed normal distribution in the K&S-
Test. The comparison between LTG serum levels
revealed a highly significant ( p = 0.00138, Fig. 1)
difference of the quotient of LTG serum level andFigure 1 Dose depending serum levels of ldosage between smokers and non-smokers. Analyz-
ing only male patients, the same relationship with
an almost equally high level of significance could be
demonstrated ( p = 0.008).
Although there was no statistically significant
correlation between the number of cigarettes per
day and LTG serum level-to-dose ratio, there was a
trend pointing to a dose effect of smoking on LTG
serum levels in the Pearson correlation
(r = 0.127 mmol/l mg, p = 0.069).Discussion
Our data indicates significant effects of smoking on
serum levels of LTG. Smokers showed a significantly
lower LTG serum level-to-dose ratio than non-smo-
kers (approximately 16%). Because our patients
were examined on various occasions and daytimes
and because a strict compliance, especially in the
outpatients of our sample, cannot be generally
assumed, this effect may even be underestimated.
Differences of multiple measurements of LTG serum
level of one patient did never exceed ranges
explained by pharmacokinetics due to various time
of LTG intake prior to the blood sampling. The
inclusion of patients with a very mild consumptionamotrigine in smokers and non-smokers.
Smoking reduces serum levels of lamotrigine 653of cigarettes (three per month) into the group of
smokers may also contribute to an underestimation
of this effect. Because the numbers in the examined
population would have been too small for statistical
analysis, it was not possible to consider only heavy
smokers in the smoker group. In addition, due to the
relatively low number of smokers, possible dose
effects of smoking could not have been detected
with statistical significance.
Since the majority of smokers were female,
whereas the majority of non-smokers were male a
possible effect of intake of oral contraceptive pills
and possible early pregnancies which were not
assessed in our study could explain the observed
difference of LTG serum level to dose ratio between
the two groups. However, the demonstration of the
same results only considering male patients points
to the relevance and validity of the overall results.
Tobacco smoke and nicotine, respectively, induce
cytochrome P450 (CYP)1A1, CYP1A2, CYP 2A1/2A2,
CYP 2B1/2B2 and CYP 2E1 as well as glucuronida-
tion,7 but these effects could only be demonstrated
in 1A9 and 2B7 subtypes of uridine diphosphate
glucuronyltransferases (UDPGT) with lorazepam,
oxazepam, propanolol and acetaminophen (parace-
tamol) as substrates so far. However, LTG is meta-
bolized by glucuronidation via UDPGT1A4,5,8 or
UDPGT2B7.8 Therefore, our data indicate that the
demonstrated effect of smoking on LTG metabolism
is likely to be mediated via UDPGT2B7, as LTG is not
a substrate of cytochrome P450 isoenzymes9 and
UDPGT1A4 activity may not be affected by nicotine,
but the exact mechanism underlying the demon-
strated effect remains uncertain.
Althoughdoubts about theusefulness of LTG serum
levels in the clinical management of patients taking
LTG remain,10 LTG serum levels are often utilized to
monitor compliance and assess tolerability and effi-
cacy.11 As smoking is still a widely spread habit in
the population smoking habits should be included
in the history of patients taking LTG and considered
in the interpretation of LTG serum levels.
Thus, our preliminary data demonstrating smok-
ing to cause a significant decrease of the LTG serumlevel-to-dose ratio has to be confirmed by further
prospective studies with a higher number of
patients, with a more detailed assessment of smok-
ing habits and hormonal issues in women.Conflict of interest
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